Elfabrio wins positive CHMP for every-4-weeks dosing in Fabry, boosting sales outlook and EU milestone potential.

Chronic Lyme disease isn't recognized by conventional medicine. It's a controversial term used by some alternative practitioners to describe pain, fatigue and neurological symptoms they attribute to a ...

Researchers at Kumamoto University have demonstrated that iron supplementation can significantly alleviate muscle pathology ...

Annexon (ANNX) stock: high-risk biotech upside from tanruprubart (GBS) & vonaprument (geographic atrophy). Read here for a ...

For much of the past decade, drug shortages in the United States were treated as episodic disruptions. In 2024, that framing ...

Researchers at Kumamoto University have demonstrated that iron supplementation can significantly alleviate muscle pathology and functional decline in a mouse model of facioscapulohumeral muscular ...

Longevity medicine has exploded into the mainstream, but the fervor has outpaced rigorous scientific evidence and federal regulations.

Preliminary total global full year 2025 revenue of approximately $616 millionPreliminary BRIUMVI U.S. fourth quarter and full year 2025 net ...

Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular ...

SGT-212 has received FDA Fast Track, Rare Pediatric Disease and Orphan Drug designations - - Dosing of the first participant in the Phase 1b FALCON trial has been completed, with initial data expected ...

The US regulator expects to issue a decision on Eisai's application for Leqembi Iqlik, which it has granted priority review, by May 24.